[go: up one dir, main page]

NO994016L - Heterocyclic Compounds and Their Use for Inhibition of <beta> Amyloid Peptide - Google Patents

Heterocyclic Compounds and Their Use for Inhibition of <beta> Amyloid Peptide

Info

Publication number
NO994016L
NO994016L NO994016A NO994016A NO994016L NO 994016 L NO994016 L NO 994016L NO 994016 A NO994016 A NO 994016A NO 994016 A NO994016 A NO 994016A NO 994016 L NO994016 L NO 994016L
Authority
NO
Norway
Prior art keywords
inhibition
beta
amyloid peptide
heterocyclic compounds
disease
Prior art date
Application number
NO994016A
Other languages
Norwegian (no)
Other versions
NO994016D0 (en
Inventor
Eugene D Thorsett
Warren J Porter
Jeffrey S Nissen
Lee H Latimer
James E Audia
James J Droste
Original Assignee
Elan Pharm Inc
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, Lilly Co Eli filed Critical Elan Pharm Inc
Publication of NO994016D0 publication Critical patent/NO994016D0/en
Publication of NO994016L publication Critical patent/NO994016L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Fremlagt er forbindelser som inhiberer D-amyloid frigivelse og/eller deres syntese, og følgelig har anvendelse ved behandling av Alzheimer's sykdom. Også fremlagt er farmasøytiske sammensetninger som innbefatter en forbindelse som inhiberer C-amyloid peptid frigivelse og/eller deres syntese såvel som fremgangsmåter for behandling av Alzheimer's sykdom både profylaktisk og terapeutisk med slike farmasøytiske sammensetninger.Presented are compounds which inhibit D-amyloid release and / or their synthesis, and consequently have utility in the treatment of Alzheimer's disease. Also disclosed are pharmaceutical compositions which include a compound which inhibits C-amyloid peptide release and / or their synthesis as well as methods of treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

NO994016A 1997-02-28 1999-08-19 Heterocyclic Compounds and Their Use for Inhibition of <beta> Amyloid Peptide NO994016L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80826397A 1997-02-28 1997-02-28
PCT/US1998/003373 WO1998038177A1 (en) 1997-02-28 1998-02-27 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING β-AMYLOID PEPTIDE

Publications (2)

Publication Number Publication Date
NO994016D0 NO994016D0 (en) 1999-08-19
NO994016L true NO994016L (en) 1999-10-18

Family

ID=25198310

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994016A NO994016L (en) 1997-02-28 1999-08-19 Heterocyclic Compounds and Their Use for Inhibition of <beta> Amyloid Peptide

Country Status (22)

Country Link
EP (1) EP0968198A1 (en)
JP (1) JP2001513107A (en)
KR (1) KR20000075767A (en)
CN (1) CN1253554A (en)
AR (1) AR011164A1 (en)
AU (1) AU6662298A (en)
BR (1) BR9807876A (en)
CA (1) CA2278674A1 (en)
CO (1) CO4920244A1 (en)
EA (1) EA199900778A1 (en)
HR (1) HRP980093A2 (en)
HU (1) HUP0001293A3 (en)
ID (1) ID22873A (en)
IL (1) IL130851A0 (en)
NO (1) NO994016L (en)
NZ (1) NZ336613A (en)
PE (1) PE59399A1 (en)
PL (1) PL335424A1 (en)
TR (1) TR199902071T2 (en)
WO (1) WO1998038177A1 (en)
YU (1) YU7998A (en)
ZA (1) ZA981627B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
AU1277799A (en) * 1997-12-22 1999-07-12 Elan Pharmaceuticals, Inc. Polycyclic alpha-amino-$m(e)-caprolactams and related compounds
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
EP1089977A1 (en) * 1998-06-22 2001-04-11 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
JP2002538151A (en) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Compounds useful as reversible inhibitors of cathepsin
US7160880B1 (en) * 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
GB9911803D0 (en) * 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
WO2001010846A2 (en) * 1999-08-05 2001-02-15 Igt Pharma Inc. 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
AU2001261728A1 (en) 2000-05-17 2001-11-26 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
BR0106717A (en) 2000-06-01 2002-04-16 Bristol Myers Squibb Pharma Co Compounds, pharmaceutical composition and uses of innovative lactam compounds
DE10029077A1 (en) * 2000-06-13 2001-12-20 Bayer Ag New heterocyclic-substituted thiazole derivatives, useful as total or selective herbicides, insecticides, acaricides, nematocides, ectoparasiticides or antifouling agents
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
FR2840899B1 (en) * 2002-06-12 2005-02-25 Sanofi Synthelabo ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS
AR039059A1 (en) 2001-08-06 2005-02-09 Sanofi Aventis COMPOUND DERIVED FROM ACILAMINOTIAZOL, ITS USE, PROCEDURES TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, AND INTERMEDIARY COMPOUNDS
CA2486350A1 (en) 2002-06-05 2003-12-24 Kaneka Corporation Process for producing optically active .alpha.-methylcysteine derivative
ATE531367T1 (en) 2004-09-17 2011-11-15 Whitehead Biomedical Inst COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING A-SYNUKLEIN POISONING
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
UA95907C2 (en) 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
CN101553476A (en) 2006-10-03 2009-10-07 阵列生物制药公司 Mitotic kinesin inhibitors and methods of use thereof
US8598346B2 (en) * 2008-07-16 2013-12-03 Bitop Ag Synthesis of cyclic amidines
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
AR081626A1 (en) 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
CN103435549A (en) * 2013-08-14 2013-12-11 无锡惠飞生物医药技术有限公司 5-methyl-7-amino-5H,7H-dibenzo[b,d]azepin-6-ketone preparation method
CN105646208B (en) * 2016-02-24 2018-10-16 潍坊晶润化工股份有限公司 The preparation method of methyl pyruvate
CN119819277B (en) * 2025-03-17 2025-05-27 昆明医科大学 A BINAM-based β-cyclodextrin derivative chiral stationary phase and its preparation method and application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11506923A (en) * 1995-06-06 1999-06-22 アセナ ニューロサイエンシーズ，インコーポレイテッド New cathepsins and methods and compositions for their inhibition

Also Published As

Publication number Publication date
YU7998A (en) 2002-06-19
TR199902071T2 (en) 2000-01-21
BR9807876A (en) 2000-02-29
CA2278674A1 (en) 1998-09-03
AR011164A1 (en) 2000-08-02
EP0968198A1 (en) 2000-01-05
NZ336613A (en) 2001-10-26
AU6662298A (en) 1998-09-18
KR20000075767A (en) 2000-12-26
WO1998038177A1 (en) 1998-09-03
HUP0001293A3 (en) 2000-09-28
HUP0001293A1 (en) 2000-08-28
JP2001513107A (en) 2001-08-28
PE59399A1 (en) 1999-06-21
PL335424A1 (en) 2000-04-25
NO994016D0 (en) 1999-08-19
CO4920244A1 (en) 2000-05-29
CN1253554A (en) 2000-05-17
IL130851A0 (en) 2001-01-28
ZA981627B (en) 1999-10-05
ID22873A (en) 1999-12-16
HRP980093A2 (en) 1998-12-31
EA199900778A1 (en) 2000-04-24

Similar Documents

Publication Publication Date Title
NO994016L (en) Heterocyclic Compounds and Their Use for Inhibition of &lt;beta&gt; Amyloid Peptide
NO992368L (en) Methods and Compounds for Inhibiting &lt;beta&gt; -amyloid Release and / or its Synthesis
NO992463L (en) N- (aryl / heteroarylacetyl) amino acid esters, pharmaceutical compositions including the same, and methods for inhibiting &lt;beta&gt; -amyloid peptide release and / or its synthesis using such compounds
BR9714358A (en) Derivatives of n- (aryl / heteroaryl) amino acid, pharmaceutical compositions comprising them, and methods for inhibiting the release of beta-amyloid peptide and / or its synthesis by using such compounds
BR9714517A (en) Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising them and processes to inhibit beta-amyloid peptide release and / or its synthesis by using such compounds
BR0212787A (en) Pharmaceutically acceptable compound or salt thereof, methods of treating or preventing disease and preparing a compound, use of a compound or salt, and pharmaceutical composition
BR0210391A (en) Compound, methods of treating a patient who has or prevent a patient from contracting a disease or condition and preparing a compound, and, using a compound
NO961326D0 (en) Inhibitors of
TR200201505T2 (en) Pirazolopyrimidines as therapeutic agents
BG101841A (en) CELLULAR ADHESION INHIBITORS
BR0210122A (en) Compound or a pharmaceutically acceptable salt thereof, method for treating or preventing a disease, use of the compound or salt thereof, and method for preparing the same
PT1037886E (en) TRIAZINE ANGIOGENESE INHIBITORS
MXPA04003245A (en) Hydroxypropylamines.
MXPA04000338A (en) Diaminediols for the treatment of alzheimer&#39;s disease.
BR0210392A (en) Compound, methods of treating a patient who has or prevent a patient from contracting a disease or condition and preparing a compound, and, using a compound
BR0115424A (en) Compound, pharmaceutical composition, methods for inhibiting the release of beta-amyloid peptide and / or its synthesis, for treating alzheimer&#39;s disease, for preventing alzheimer&#39;s disease, and for inhibiting the progress of alzheimer&#39;s disease, processes for preparing the compound , and to prepare lactams, and, use of compound
BR0113590A (en) 7-oxopyridopyrimidines
DE69917005D1 (en) SUBSTITUTED PYRROLOBENZIMIDAZOLE DERIVATIVES FOR ANTI-INFLAMMATION
BR0314180A (en) Substituted Aminoethers for the Treatment of Alzheimer&#39;s Disease
MXPA04000337A (en) Aminediols for the treatment of alzheimer&#39;s disease.
WO2000033788A3 (en) Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
WO2001034639A3 (en) β-AMINOACID COMPOUNDS USEFUL FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS
WO2004029019A3 (en) Compounds for the treatment of alzheimer’s disease
MX9701528A (en) 1,1,2-triphenylbut-1-ene derivatives for treating alzheimers disease.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application